Retseptor faktora rosta fibroblastov 1-go tipa kak mishen' tselenapravlennoy terapii pochechno-kletochnogo raka
- 作者: Timofeev I.1,2
-
隶属关系:
- Бюро по изучению рака почки
- Общество онкологов-химиотерапевтов, Москва
- 期: 卷 15, 编号 3 (2013)
- 页面: 56-62
- 栏目: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26915
- ID: 26915
如何引用文章
全文:
详细
Патогенетический путь фактора роста фибробластов и его рецепторов имеет большое значение в развитии и прогрессировании почечно-клеточного рака. Различные его компоненты рассматриваются в качестве мишеней таргетной терапии. Возможно, в ближайшем будущем появятся новые препараты, которые повысят общую эффективность терапии метастатического рака почки и других опухолей.
作者简介
Il'ya Timofeev
Бюро по изучению рака почки; Общество онкологов-химиотерапевтов, Москвадир. Бюро по изучению рака почки, дир. Общества онкологов-химиотерапевтов, член научного комитета Международной ассоциации по борьбе с раком почки
参考
- Kluger H.M, Siddiqui S.F, Angeletti C et al. Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Laboratory Investigation 2008; 88: 962–72.
- Rini B.I, Atkins M.B. Resistance to targeted therapy in renal - cell carcinoma. Lancet Oncol 2009; 10: 992–1000.
- Saylor P.J, Escudier B, Michaelson M.D. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy. Clin Genitourin Cancer 2012; 10 (2): 77–83.
- Fernando N.T, Koch M, Rothrock C et al. Tumor escape from endogenous, extracellular matrix - associated angiogenesis inhibitors by up - regulation of multiple proangiogenic factors. Clin Cancer Res 2008; 14: 1529–39.
- Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Dis 2009; 8: 235–53.
- Eswarakumar V.P, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16: 139–49.
- Brooks A.N, Kilgour E, Smith P.D. Molecular pathways: fibroblast growth factor signaling. A new therapeutic opportunity in cancer. Clin Cancer Res 2012; 18: 1855–62.
- Tomlinson D.C, Knowles M.A. Altered splicing of FGFR-1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF-1 in bladder cancer. Am J Pathol 2010; 177 (5): 2379–86.
- Abuharbeid S, Czubayko F, Aigner A. The fibroblast growth factor - binding protein FGF-BP. Int J Biochem Cell Biol 2006; 38 (9): 1463–8.
- Turner N, Grose R. Fibroblast growth factor signaling: from development to cancer. Nat Rev Cancer 2010; 10 (2): 116–29.
- Tsimafeyeu I, Demidov L, Stepanova E, Wynn N. Overexpression of fibroblast growth factor receptors FGFR-1 and FGFR-2 in renal cell carcinoma. Scandinav J Urol Nephrol 2011; 3: 190–5.
- Ho T et al. The role of FGF signaling in VEGF-pathway targeted therapy resistance. Data from patients and model systems. J Clin Oncol 2013; 31 (Suppl. 6). Abstr. 386.
- Tsimafeyeu I, Wynn N, Gordiyev M, Khasanova A. FGFR-2 expression and mutation are rare in papillary renal cell carcinoma. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research 2013 Apr 6–10. Washington DC. Philadelphia PA: AACR. Cancer Res 2013; 73 (Suppl. 8). Abstr. 4069.
- Stoehr C.G et al. Mutational activation of FGFR-3: no involvement in the development of renal cell carcinoma. J Cancer Res Clin Oncol 2012; 138 (2): 359–61.
- Hsu T, Adereth Y, Kose N, Dammai V. Endocytic function of von Hippel–Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility. J Biol Chem 2006; 281 (17): 12 069–80.
- Тимофеев И.В., Демидов Л.В., Степанова Е.В. и др. Роль фактора роста фибробластов и его рецептора в патогенезе почечно - клеточного рака. Онкоурология. 2011; с. 247–8.
- Porto C et al. Changes in circulating pro - angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. Oncol 2013; 84 (2): 115–22.
- Tsimafeyeu I, Demidov L, Ta H et al. Fibroblast growth factor pathway in renal cell carcinoma. J Clin Oncol 2010; 28: 15s. Abstr. 4621.
- Mydlo J.H, Kral J.G, Macchia R.J. Preliminary results comparing the recovery of basic fibroblast growth factor (FGF-2) in adipose tissue and benign and malignant renal tissue. J Urol 1998; 159 (6): 2159–63.
- Avnet S et al. Interferon - a inhibits in vitro osteoclast differentiation and renal cell carcinoma - induced angiogenesis. Int J Oncol 2007; 30 (2): 469–76.
- Cenni E et al. Inhibition of angiogenesis via FGF-2 blockage in primitive and bone metastatic renal cell carcinoma. Anticancer Res 2007; 27 (1): 315–9.
- Bahramsoltani M, De Spiegelaere W, Janczyk P et al. Quantitation of angiogenesis in vitro induced by VEGF-A and FGF-2 in two different human endothelial cultures – an all - in - one assay. Clin Hemorheol Microcirc 2010; 46 (2–3): 189–202.
- Tsimafeyeu I, Demidov L, Wynn N. A role of the FGF-pathway in the VEGF/VEGFR targeting. Cancer Research 2011; 71: 5157.
- Cao R, Bråkenhielm E, Pawliuk R et al. Angiogenic synergism, vascular stability and improvement of hind - limb ischemia by a combination of PDGF-BB and FGF-2. Nat Wed 2003; 9 (5): 604–13.
- Murakami M, Nguyen L.T, Hatanaka K et al. FGF-dependent regulation of VEGF receptor 2 expression in mice. J Clin Inv 2011; 121 (7): 2668–78.
- Lee S.H, Schloss D.J, Swain J.L. Maintenance of vascular integrity in the embryo requires signaling through the fibroblast growth factor receptor. J Biol Chem 2000; 275 (43): 33 679–87.
- Dell'Era P, Belleri M, Stabile H et al. Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells. Oncogene 2001; 20 (21): 2655–63.
- Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med 1997; 3 (8): 887–93.
- Birrer M.J, Johnson M.E, Hao K et al. Whole genome oligonucleotide - based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced - stage serous ovarian adenocarcinomas. J Clin Oncol 2007; 25 (16): 2281–7.
- Presta M, Dell'Era P, Mitola S et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16 (2): 159–78.
- Underwood P.A, Bean P.A, Gamble J.R. Rate of endothelial expansion is controlled by cell: cell adhesion. Int J Biochem Cell Biol 2002; 34 (1): 55–69.
- El Hariry I, Pignatelli M, Lemoine N.R. FGF-1 and FGF-2 modulate the E-cadherin/catenin system in pancreatic adenocarcinoma cell lines. Br J Cancer 2001; 84 (12): 1656–63.
- Elfenbein A, Simons M. Syndecan-4 signaling at a glance. J Cell Sci 2013; 126 (17): 3799–804.
- Mori S, Tran V, Nishikawa K et al. A dominant - negative FGF-1 mutant (the R50E mutant) suppresses tumor genesis and angiogenesis. PLoS One 2013; 8 (2): e57 927.
- Seghezzi G, Patel S, Ren C.J et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 1998; 141 (7): 1659–73.
- Tsunoda S, Nakamura T, Sakurai H, Saiki I. Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization. Cancer Sci 2007; 98 (4): 541–8.
- Gozgit J.M, Wong M.J, Moran L et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 2012; 11: 690–9.
- Lee S.H, Lopes de Menezes D, Vora J et al. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 2005; 11 (10): 3633–41.
- Zhen Wei C, Yongzheng Zh, Borzilleri R et al. Discovery of Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate). A novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chemist 2008; 51 (6): 1976–80.
- Hilberg F, Roth G.J, Krssak M et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68 (12): 4774–82.
- Matsui J, Funahashi Y, Uenaka T et al. Multi - kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor - receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008; 14 (17): 5459–65.
- Zhao G, Li W, Chen D et al. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol Cancer Ther 2011; 10: 2200–10.
- Gavine P.R, Mooney L, Kilgour E et al. AZD 4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 2012; 72 (8): 2045–56.
- Guagnano V, Furet P, Spanka C et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy - phenyl)-1-{6-[4-(4-ethyl - piperazin-1-yl)- phenylamino] - pyrimidin-4-yl}-1-methyl - urea (NVP-BGJ398). A potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 2011; 54 (20): 7066–83.
- Siu L et al. Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild - type (WT), metastatic colorectal carcinoma (mCRC). The NCIC Clinical Trials Group and AGITG CO 20 trial. J Clin Oncol 2012; 30. Abstr. 3504.
- Reck M et al. Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first - line chemotherapy: LUME Lung 1, a randomized, double - blind phase III trial. J Clin Oncol 2013; 31. Abstr. LBA 8011.
- Eisen T et al. Phase II efficacy and safety study of nintedanib vs sunitinib in previously untreated renal cell carcinoma (RCC) patients. J Clin Oncol 2013; 31. Abstr. 4506.
- Maio M et al. Lenvatinib combined with dacarbazine vs dacarbazine alone as first - line treatment in patients with stage IV melanoma. J Clin Oncol 2013; 31. Abstr. 9027.
- Schlumberger M et al. A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC). J Clin Oncol 2012; 30. Abstr. 5591.
- Tsimafeyeu I.V, Zaveleva E, Low W. Preclinical activity of OM-RCA-01, a humanized anti-FGFR1 antibody, in renal cell carcinoma (RCC). Cancer Res 2012; 72 (Suppl. 8): 2848.
- Bai A, Meetze K, Vo N.Y et al. GP369, an FGFR2-IIIb - specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR-2 signaling. Cancer Res 2010; 70 (19): 7630–9.
- Motzer R et al. Phase 3 trial of dovitinib vs sorafenib in patients with metastatic renal cell carcinoma after 1 prior VEGF pathway - targeted and 1 prior mTOR inhibitor therapy. Eur Cancer Congress 2013. Abstr. 34.
- Angevin E, Grünwald V, Ravaud A et al. A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). J Clin Oncol 2011; 29. Abstr. 4551.
- Kim K.B, Chesney J, Robinson D et al. Phase I–II and pharmacodynamic study of dovitinib (TKI 258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res 2011; 17 (23): 7451–61.
- Okamoto I, Kaneda H, Satoh T et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther 2010; 9 (10): 2825–33.
- Tsimafeyeu I, Zaveleva E, Low W. OM-RCA-01, an FGFR1 specific humanized antibody for the treatment of renal cell carcinoma (RCC). J Clin Oncol 2012; 30. Abstr. 3070.
- Tsimafeyeu I, Zaveleva E, Tolkacheva T. Does dose - dependent targeting of fibroblast growth factor (FGF) receptor 1 (FGFR1) impact on growth of renal cell carcinoma? Proceedings of the 27th Annual Congress of the European Association of Urology 2012. Abstr. 306.
- Tsimafeyeu I, Zaveleva E, Stepanova E, Low W. OM-RCA-01, a novel humanized monoclonal antibody targeting fibroblast growth factor receptor 1, in renal cell carcinoma model. Invest New Drugs 2013.
- Sun H.D, Malabunga M, Tonra J.R et al. Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys. Am J Physiol Endocrin Metabol 2007; 292 (3): e964–76.
- Trudel S.A, Stewart K, Rom E et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 2006; 107: 4039–46.
- Qing J, Du X, Chen Y, Chan P. Antibody - based targeting of FGFR-3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Inv 2009; 119 (5): 1216–29.
- Park H, Wang L, Chim S et al. HuGAL-FR 21, a humanized monoclonal antibody to Fibroblast Growth Factor Receptor 2, effectively inhibits the growth of gastric tumor xenografts. Cancer Res 2011; 71 (Suppl. 8): 5056.
- Harding T.C, Long L, Palencia S et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci Transl Med 2013; 5 (178): 39.
- http://clinicaltrials.gov/ct2/show/NCT01868022?term= NCT01868022&rank=1